Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Walmsley, B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, M. Johnson, David Johnson, R. Lalonde, A. Japour, S. Brun, E. Sun (2002)
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.The New England journal of medicine, 346 26
Demonstrated that this nucleos(t)ide combination was suboptimal and should not be used in initiating treatment
G. Moyle, C. Higgs, A. Teague, S. Mandalia, M. Nelson, M. Johnson, M. Fisher, B. Gazzard (2006)
An Open-Label, Randomized Comparative Pilot Study of a Single-Class Quadruple Therapy Regimen versus a 2–Class Triple Therapy Regimen for Individuals Initiating Antiretroviral TherapyAntiviral Therapy, 11
(2004)
Efficacy and safety of atazanavirbased therapy in antiretroviral naive HIV - 1 infected subjects , both with and without ritonavir : 48week results from AI 424089
C. Goujard, M. Bonarek, L. Meyer, F. Bonnet, M. Chaix, C. Deveau, M. Sinet, J. Galimand, J. Delfraissy, A. Venet, C. Rouzioux, P. Morlat (2006)
CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 42 5
for the SMART Study Investigators. Episodic CD4-guided use of ART is inferior to continuous therapy: results of the SMART Study
Heather McDonald, Amit Garg, R. Haynes (2002)
Interventions to enhance patient adherence to medication prescriptions: scientific review.JAMA, 288 22
F. Lampe, J. Gatell, S. Staszewski, Margaret Johnson, C. Pradier, M. Gill, E. Làzzari, B. Dauer, M. Youle, E. Fontas, H. Krentz, A. Phillips (2006)
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.Archives of internal medicine, 166 5
(2004)
Virological outcome of TDF plus ABCbased regimens in previously HIV suppressed patients ( 24 wk preliminary results from RECOVER study )
Abstract TuPeB4544
J. Kiser, P. Anderson, T. Kakuda (2004)
6th International Workshop on Clinical Pharmacology of HIV TherapyExpert Opinion on Pharmacotherapy, 7
C. Fundarò, O. Genovese, C. Rendeli, E. Tamburrini, E. Salvaggio (2002)
Myelomeningocele in a child with intrauterine exposure to efavirenz.AIDS, 16 2
E. Wood, R. Hogg, B. Yip, D. Moore, P. Harrigan, J. Montaner (2006)
Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥ 200 cells/μlAIDS, 20
Boosted PI are more forgiving of suboptimal adherence than nonboosted PI or NNRTI
Update of summary of product characteristics
S. Mannheimer, E. Morse, J. Matts, L. Andrews, C. Child, B. Schmetter, G. Friedland (2006)
Sustained Benefit From a Long-Term Antiretroviral Adherence Intervention: Results of a Large Randomized Clinical TrialJAIDS Journal of Acquired Immune Deficiency Syndromes, 43
D. Podzamczer, E. Ferrer, E. Consiglio, J. Gatell, Pepa Pérez, J. Pérez, Elena Luna, Alicia González, E. Pedrol, L. Lozano, I. Ocaña, J. Llibre, A. Casiró, M. Aranda, P. Barrufet, J. Martínez‐Lacasa, J. Miro, X. Badia, A. Casado, S. Lupo, P. Cahn, M. Mañós, J. Estela (2001)
A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study)Antiviral Therapy, 7
Sustained efficacy of nevirapine ( NVP ) in combination with two nucleosides in advanced treatmentnaive HIV infected patients with high viral loads : a B 1090 substudy
(2000)
Retrospective analysis of factors associated with discontinuation of EFV due to adverse effects
Early nonresponse to TDF DF ( TDF ) þ abacavir ( ABC ) and lamivudine ( 3 TC ) in a randomized trial compared to efavirenz ( EFV ) þ ABC þ 3 TC : ESS 30009 unplanned interim analysis
E. Dejesus, G. Herrera, E. Teófilo, J. Gerstoft, Carlos Buendía, J. Brand, C. Brothers, Jaime Hernandez, Steve Castillo, T. Bonny, E. Lanier, T. Scott (2004)
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 39 7
J. Parienti, V. Massari, D. Descamps, A. Vabret, E. Bouvet, B. Larouzé, R. Verdon (2004)
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 38 9
R. Leeuwen, C. Katlama, R. Murphy, K. Squires, J. Gatell, A. Horban, B. Clotet, S. Staszewski, A. Eeden, N. Clumeck, M. Moroni, A. Pavia, R. Schmidt, J. González-Lahoz, J. Montaner, F. Antunes, R. Gulick, D. Bánhegyi, M. Valk, P. Reiss, Liesbeth Weert, F. Leth, V. Johnson, J. Sommadossi, J. Lange (2003)
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patientsAIDS, 17
Impact of directly observed therapy on outcomes in HIV clinical trials
S. Hammer, Kathleen Squires, M. Hughes, Michael Hughes, J. Grimes, L. Demeter, J. Currier, J. Eron, J. Feinberg, H. Balfour, L. Deyton, J. Chodakewitz, M. Fischl, J. Phair, W. Spreen, L. Pedneault, B. Nguyen, Jon Cook (1997)
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.The New England journal of medicine, 337 11
J. Gallant, E. Dejesus, J. Arribas, A. Pozniak, B. Gazzard, R. Campo, B. Lu, D. Mccoll, S. Chuck, J. Enejosa, J. Toole, A. Cheng (2006)
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.The New England journal of medicine, 354 3
U. Dragsted, J. Gerstoft, C. Pedersen, B. Peters, A. Durán, N. Obel, A. Castagna, P. Cahn, N. Clumeck, J. Bruun, J. Benetucci, A. Hill, I. Cassetti, P. Vernazza, M. Youle, Z. Fox, J. Lundgren (2003)
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.The Journal of infectious diseases, 188 5
I. Sanne, P. Piliero, K. Squires, A. Thiry, S. Schnittman (2003)
Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 32
J. Mellors, A. Muñoz, J. Giorgi, J. Margolick, C. Tassoni, Phalguni Gupta, L. Kingsley, J. Todd, A. Saah, R. Detels, J. Phair, Charles Jr. (1997)
Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 InfectionAnnals of Internal Medicine, 126
G. Moyle, E. Dejesus, P. Cahn, Steve Castillo, Henry Zhao, D. Gordon, C. Craig, T. Scott (2005)
Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults: Results of the Ziagen Once Daily in Antiretroviral Combination StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 38
M. Egger, M. May, G. Chêne, A. Phillips, B. Ledergerber, F. Dabis, D. Costagliola, A. Monforte, F. Wolf, P. Reiss, J. Lundgren, A. Justice, S. Staszewski, C. Leport, R. Hogg, C. Sabin, J. Gill, B. Salzberger, J. Sterne (2002)
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studiesThe Lancet, 360
A. Phillips, G. Smith, M. Johnson (1996)
For Debate: Will we ever know when to treat HIV infection?BMJ, 313
B. Kearney, J. Flaherty, J. Shah (2004)
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.Clinical Pharmacokinectics, 43
Poor virological responses and early emergence of resistance in treatment naı̈ve , HIV - infected patients receiving a once daily triple nucleoside regimen of didanosine , lamivudine , and TDF DF
M. Baylor, R. Johann‐Liang (2004)
Hepatotoxicity associated with nevirapine use.Journal of acquired immune deficiency syndromes, 35 5
J. Bartlett, M. Fath, R. Demasi, A. Hermes, Joseph Quinn, E. Mondou, F. Rousseau (2006)
An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adultsAIDS, 20
Graeme Moyle, Courtney Fletcher, H. Brown, Sundhiya Mandalia, B. Gazzard (2006)
Changes in sleep quality and brain wave patterns following initiation of an efavirenz‐containing triple antiretroviral regimenHIV Medicine, 7
A. Wohl, W. Garland, R. Valencia, K. Squires, M. Witt, A. Kovacs, R. Larsen, S. Hader, M. Anthony, P. Weidle (2006)
A randomized trial of directly administered antiretroviral therapy and adherence case management intervention.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 42 11
F. Leth, P. Phanuphak, K. Ruxrungtham, E. Baraldi, S. Miller, B. Gazzard, P. Cahn, U. Lalloo, IP Westhuizen, Malan, Margaret Johnson, B. Santos, F. Mulcahy, R. Wood, GC Levi, G. Reboredo, K. Squires, I. Cassetti, D. Petit, F. Raffi, C. Katlama, R. Murphy, A. Horban, JP Dam, E. Hassink, R. Leeuwen, P. Robinson, F. Wit, J. Lange (2004)
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyThe Lancet, 363
G. Lucas, B. Mullen, P. Weidle, S. Hader, M. Mccaul, Richard Moore (2006)
Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 42 11
T. Sterling, R. Chaisson, Richard Moore (2001)
HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapyAIDS, 15
(2005)
Cognitive - behavioral intervention to enhance adherence to ART : a randomized clinical trial ( CCTG 578 )
R. Gulick, J. Mellors, D. Havlir, J. Eron, C. González, D. McMahon, D. Richman, F. Valentine, L. Jonas, A. Meibohm, E. Emini, J. Chodakewitz (1997)
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.The New England journal of medicine, 337 11
A. Phillips, P. Pezzotti (2003)
Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy eraAIDS, 18
J. Phair, J. Mellors, R. Detels, J. Margolick, A. Muñoz (2002)
Virologic and immunologic values allowing safe deferral of antiretroviral therapyAIDS, 16
Schlomo Staszewski, P. Keiser, J. Montaner, F. Raffi, J. Gathe, V. Brotas, C. Hicks, S. Hammer, David Cooper, Margaret Johnson, Stephanie Tortell, A. Cutrell, D. Thorborn, R. Isaacs, Seth Hetherington, H. Steel, W. Spreen (2001)
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.JAMA, 285 9
Schlomo Staszewski, J. Morales-Ramirez, K. Tashima, A. Rachlis, D. Skiest, James Stanford, R. Stryker, P. Johnson, Dominic Labriola, Dianne Farina, D. Manion, N. Ruiz (1999)
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.The New England journal of medicine, 341 25
R. Landman, D. Descamps, G. Peytavin, A. Trylesinski, C. Katlama, P. Girard, B. Bonnet, P. Yeni, M. Bentata, C. Michelet, A. Benalycherif, F. Vezinet, M.D. Miller, P. Flandre (2005)
Early Virologic Failure and Rescue Therapy of Tenofovir, Abacavir, and Lamivudine for Initial Treatment of HIV-1 Infection: TONUS StudyHIV Clinical Trials, 6
A. Phillips, A. Lepri, F. Lampe, M. Johnson, C. Sabin (2003)
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studiesAIDS, 17
Virologic efficacy of three oncea - day HAART regimens : planned interim analysis
CD 4guided scheduled treatment interruptions : low incidence of resistance mutations in the Staccato trial
J. Gallant, S. Staszewski, A. Pozniak, E. Dejesus, J. Suleiman, Michael Miller, D. Coakley, B. Lu, J. Toole, A. Cheng (2004)
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA, 292 2
D. Cameron, M. Heath-Chiozzi, S. Danner, C. Cohen, S. Kravcik, C. Maurath, E. Sun, D. Henry, R. Rode, A. Potthoff, J. Leonard (1998)
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 351
(2004)
Toxicity and efficacy of 3 TC / EFV associated with stavudine or abacavir in antiretroviralnaı̈ve patients : 48 week results of a randomized open and multicentre trial ( ABCDE study )
Annalise Martin, D. Nolan, S. Gaudieri, C. Almeida, R. Nolan, I. James, F. Carvalho, E. Phillips, F. Christiansen, A. Purcell, J. McCluskey, S. Mallal (2004)
Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variantProceedings of the National Academy of Sciences of the United States of America, 101
D. Maitland, G. Moyle, J. Hand, S. Mandalia, M. Boffito, M. Nelson, B. Gazzard (2005)
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trialAIDS, 19
C. Smit, R. Geskus, S. Walker, C. Sabin, R. Coutinho, K. Porter, M. Prins (2006)
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversionAIDS, 20
No differences were found in virologic or immunologic response for DOT or intense adherence measures, compared with standard of care
K. Squires, A. Lazzarin, J. Gatell, W. Powderly, V. Pokrovskiy, J. Delfraissy, J. Jemsek, A. Rivero, Willy Rozenbaum, S. Schrader, M. Sension, A. Vibhagool, A. Thiry, Michael Giordano (2004)
Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIVJAIDS Journal of Acquired Immune Deficiency Syndromes, 36
S. López, Ò. Miró, E. Martinez, E. Pedrol, B. Rodríguez-Santiago, A. Milinkovic, A. Soler, M. García-Viejo, V. Nunes, J. Casademont, J. Gatell, F. Cardellach (2004)
Mitochondrial Effects of Antiretroviral Therapies in Asymptomatic PatientsAntiviral Therapy, 9
Felipe García, E. Làzzari, M. Plana, P. Castro, G. Mestre, M. Nomdedeu, E. Fumero, E. Martinez, J. Mallolas, J. Blanco, J. Miro, T. Pumarola, T. Gallart, J. Gatell (2004)
Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell CountJAIDS Journal of Acquired Immune Deficiency Syndromes, 36
U . S . surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera
Non nucleoside reverse transcriptase inhibitor ( NNRTI ) resistance occurs at lower levels of adherence then protease inhibitor ( PI ) resistance
Initial therapy with abacavir þ lamivudine ( ABC þ 3 TC ) combined with efavirenz ( NNRTI ) , amprena - vir / ritonavir ( PI ) or stavudine ( NRTI ) : ESS 40001 ( CLASS )
R. Gulick, H. Ribaudo, C. Shikuma, S. Lustgarten, K. Squires, W. Meyer, E. Acosta, B. Schackman, C. Pilcher, R. Murphy, W. Maher, M. Witt, R. Reichman, S. Snyder, K. Klingman, D. Kuritzkes (2004)
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.The New England journal of medicine, 350 18
D. Bangsberg, F. Hecht, E. Charlebois, A. Zolopa, M. Holodniy, L. Sheiner, J. Bamberger, M. Chesney, A. Moss (2000)
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent populationAIDS, 14
K. Bhaskaran, R. Brettle, K. Porter, A. Walker (2004)
Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictorsAIDS, 18
J. Walsh, A. Pozniak, M. Nelson, S. Mandalia, B. Gazzard (2002)
Virologic Rebound on HAART in the Context of Low Treatment Adherence Is Associated With a Low Prevalence of Antiretroviral Drug ResistanceJAIDS Journal of Acquired Immune Deficiency Syndromes, 30
M. Nunez, V. Soriano, L. Martín-Carbonero, A. Barrios, P. Barreiro, F. Blanco, T. García-Benayas, J. González-Lahoz (2002)
SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individualsHIV Clinical Trials, 3
This discusses the issues around CD4 thresholds for use of nevirapine and its use as a once-daily drug
U. Dragsted, J. Gerstoft, M. Youle, Z. Fox, M. Losso, J. Benetucci, D. Jayaweera, A. Rieger, J. Bruun, A. Castagna, B. Gazzard, S. Walmsley, A. Hill, J. Lundgren (2005)
A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 TrialAntiviral Therapy, 10
T. Sterling, R. Chaisson, Richard Moore (2003)
Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 36 6
R. Hogg, B. Yip, Keith Chan, E. Wood, K. Craib, M. O'Shaughnessy, J. Montaner (2001)
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.JAMA, 286 20
J. Gallant, Allan Rodriguez, W. Weinberg, B. Young, D. Berger, Michael Lim, Qiming Liao, L. Ross, Judy Johnson, M. Shaefer (2005)
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.The Journal of infectious diseases, 192 11
R. Murphy, I. Sanne, P. Cahn, P. Phanuphak, Lisa Percival, T. Kelleher, Michael Giordano (2003)
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week resultsAIDS, 17
A. Wensing, D. Vijver, G. Angarano, B. Åsjö, C. Balotta, E. Boeri, R. Camacho, M. Chaix, D. Costagliola, A. Luca, I. Derdelinckx, Z. Grossman, O. Hamouda, A. Hatzakis, R. Hemmer, A. Hoepelman, A. Horban, K. Korn, C. Kücherer, T. Leitner, C. Loveday, E. Macrae, I. Maljkovic, C. Mendoza, L. Meyer, C. Nielsen, E. Coul, V. Ormaasen, D. Paraskevis, L. Perrin, E. Puchhammer-Stöckl, L. Ruíz, M. Salminen, J. Schmit, F. Schneider, R. Schuurman, V. Soriano, G. Stańczak, M. Stanojevic, A. Vandamme, K. Laethem, M. Violin, Karin Wilbe, S. Yerly, M. Zazzi, C. Boucher (2005)
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.The Journal of infectious diseases, 192 6
Psychiatric safety of efavirenz
ART Cohort Collaboration . Estimating the optimum CD 4 threshold for starting HAART in ARTnaive HIV - infected individuals
G. Robbins, V. Gruttola, R. Shafer, L. Smeaton, S. Snyder, C. Pettinelli, M. Dubé, M. Fischl, R. Pollard, R. Delapenha, Linda Gedeon, C. Horst, R. Murphy, M. Becker, R. D’Aquila, S. Vella, T. Merigan, M. Hirsch (2003)
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.The New England journal of medicine, 349 24
M. LethvanF.C., S. Andrews, B. Grinsztejn, E. Wilkins, M. Lazanas, J. Lange, J. Montaner (2005)
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAARTAIDS, 19
N. Friis‐Møller, P. Reiss, W. El-Sadr, A. Monforte, R. Thiébaut, S. Wit, R. Weber, E. Fontas, M. Law, A. Phillips, J. Lundgren (2006)
Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D study group
A. Monforte, C. Sabin, A. Phillips, J. Sterne, M. May, A. Justice, F. Dabis, S. Grabar, B. Ledergerber, J. Gill, P. Reiss, M. Egger (2005)
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.Archives of internal medicine, 165 4
A. Ray, L. Olson, A. Fridland (2004)
Role of Purine Nucleoside Phosphorylase in Interactions between 2′,3′-Dideoxyinosine and Allopurinol, Ganciclovir, or TenofovirAntimicrobial Agents and Chemotherapy, 48
Anton Pozniak Purpose of review Introduction Until there is a therapy or a vaccine that can eradicate HIV The marked decline in annual AIDS-related mortality infection, it is important to continue debating the issues of and morbidity over the past 10 years is largely accredited when and how to use the many antiviral agents licensed as to the widespread introduction of highly active antire- initial treatment since there remain many areas of troviral therapy (HAART) in 1995. The Antiretroviral uncertainty. Therapy Cohort Collaboration found a decline in Recent findings incidence of AIDS-defining events among 12 574 anti- Early initiation of treatment may be beneficial in terms of HIV retroviral-naive individuals from 129.3 per 1000 person- progression but it has to be weighed against the risks of years in the first 3 months after starting HAART to 13.2 in adverse drug side effects and complications. In first-line the third year after starting HAART (P< 0.001) [1 ]. treatment the choice of nucleoside backbones has become limited due to the availability of once a day combined The most common cause of death pre-HAART was formulations which have excellent short and long-term AIDS opportunistic infections, but in the HAART era side-effect profiles.
Current Opinion in HIV and Aids – Wolters Kluwer Health
Published: Sep 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.